SG11202101789SA - Method for generating cells into which an exogenous antigen receptor is introduced - Google Patents

Method for generating cells into which an exogenous antigen receptor is introduced

Info

Publication number
SG11202101789SA
SG11202101789SA SG11202101789SA SG11202101789SA SG11202101789SA SG 11202101789S A SG11202101789S A SG 11202101789SA SG 11202101789S A SG11202101789S A SG 11202101789SA SG 11202101789S A SG11202101789S A SG 11202101789SA SG 11202101789S A SG11202101789S A SG 11202101789SA
Authority
SG
Singapore
Prior art keywords
antigen receptor
exogenous antigen
generating cells
cells
generating
Prior art date
Application number
SG11202101789SA
Other languages
English (en)
Inventor
Hiroshi Kawamoto
Yasutoshi Agata
Seiji Nagano
Koji Terada
Kyoko Masuda
Original Assignee
Univ Kyoto
National Univ Corporation Shiga Univ Of Medical Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyoto, National Univ Corporation Shiga Univ Of Medical Science filed Critical Univ Kyoto
Publication of SG11202101789SA publication Critical patent/SG11202101789SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
SG11202101789SA 2018-07-26 2019-07-26 Method for generating cells into which an exogenous antigen receptor is introduced SG11202101789SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018140523 2018-07-26
PCT/JP2019/029537 WO2020022512A1 (ja) 2018-07-26 2019-07-26 外来抗原レセプター遺伝子導入細胞の製造方法

Publications (1)

Publication Number Publication Date
SG11202101789SA true SG11202101789SA (en) 2021-03-30

Family

ID=69180441

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101789SA SG11202101789SA (en) 2018-07-26 2019-07-26 Method for generating cells into which an exogenous antigen receptor is introduced

Country Status (7)

Country Link
US (1) US20210381008A1 (cg-RX-API-DMAC7.html)
EP (1) EP3845638A4 (cg-RX-API-DMAC7.html)
JP (1) JP7422365B2 (cg-RX-API-DMAC7.html)
CN (1) CN112752838A (cg-RX-API-DMAC7.html)
AU (1) AU2019312008B2 (cg-RX-API-DMAC7.html)
SG (1) SG11202101789SA (cg-RX-API-DMAC7.html)
WO (1) WO2020022512A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006903D0 (en) * 2020-05-11 2020-06-24 Adaptimmune Ltd Modified iPSCs
JPWO2022059780A1 (cg-RX-API-DMAC7.html) * 2020-09-18 2022-03-24
EP4219707A4 (en) * 2020-09-24 2024-11-13 Kyoto University METHOD FOR PRODUCING AN EFFECTOR CELL WITH DESIRED SPECIFICITY
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CA3213440A1 (en) * 2021-04-16 2022-10-20 Thyas Co. Ltd. A cell bank composed of ips cells for transfecting t cell receptor gene
JP2025500531A (ja) * 2021-12-27 2025-01-09 グラセル バイオテクノロジーズ(シャンハイ)カンパニー,リミテッド 細胞改変のための系及び方法
JPWO2025033358A1 (cg-RX-API-DMAC7.html) * 2023-08-04 2025-02-13

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1409646T3 (da) 2000-12-19 2012-08-06 Altor Bioscience Corp Transgene dyr omfattende et humaniseret immunsystem
JPWO2011096482A1 (ja) 2010-02-03 2013-06-13 国立大学法人 東京大学 多能性幹細胞を用いた免疫機能再建法
RS61455B1 (sr) 2011-10-28 2021-03-31 Regeneron Pharma Genetski modifikovani miševi t ćelijskog receptora
EP2853590B1 (en) 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
EP3789487A1 (en) 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
US20170296649A1 (en) * 2014-07-18 2017-10-19 Hiroshi Kawamoto Method for inducing t cells for cell-based immunotherapy
US12194083B2 (en) * 2014-07-18 2025-01-14 Hiroshi Kawamoto Method for establishing pluripotent stem cells bearing genes encoding antigen specific T cell receptor
EP3170895A4 (en) 2014-07-18 2018-07-11 Kawamoto, Hiroshi Production method for pluripotent stem cells having antigen-specific t cell receptor gene
CN105316362B (zh) * 2015-08-19 2020-03-17 暨南大学 一种Dual-RMCE介导的TCR基因置换系统及其方法
US12642852B1 (en) * 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
KR102614675B1 (ko) * 2016-04-15 2023-12-19 메모리얼 슬로안 케터링 캔서 센터 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
LT3444334T (lt) 2016-04-15 2021-12-10 Kyoto University Antigenui specifinių cd8 teigiamų t ląstelių indikavimo būdas

Also Published As

Publication number Publication date
AU2019312008B2 (en) 2026-04-23
JPWO2020022512A1 (ja) 2021-08-02
EP3845638A4 (en) 2022-05-11
US20210381008A1 (en) 2021-12-09
CN112752838A (zh) 2021-05-04
AU2019312008A1 (en) 2021-03-18
EP3845638A1 (en) 2021-07-07
WO2020022512A1 (ja) 2020-01-30
JP7422365B2 (ja) 2024-01-26

Similar Documents

Publication Publication Date Title
SG11202102003TA (en) Methods of generating an array
IL254511B (en) A method for identifying new immunogenic epitopes of t cells and isolation of antigen-specific and new t cell receptors using a cellular mhc library
PT3580330T (pt) Método para gerar progenitores de células t
SG11202100156UA (en) Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells
SG11202106678PA (en) Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
IL280571A (en) Device for beams with multiple charged particles
GB2585261B (en) Methods for generating modified images
SG11202007563XA (en) Method for producing low-antigenic cell
HUE056387T2 (hu) Eljárás antigénspecifikus CD8-pozitív T-sejtek indukálására
EP3277294A4 (en) Method of identifying human compatible t cell receptors specific for an antigenic target
GB2587988B (en) Method for enhancing the suppressive properties of Treg cells
SG11202104962QA (en) Dendritic cell generating apparatus and method
IL253627A0 (en) Prediction of t-cell epitopes used for vaccination
IL279172A (en) Methods for the production of hematopoietic stem cells
SG11202103745WA (en) Method for activation/proliferation of t cells
HUE049347T2 (hu) Antigénspecifikus T-sejt-receptor génjét tartalmazó pluripotens õssejtek elõállítására szolgáló eljárás
SG11202100829SA (en) Method for producing cd3-positive cell
SG11202105449VA (en) Method for separating cell culture mixture
IL273564A (en) Device for using charged particle beams
GB201819928D0 (en) Method for generating persulfate
PL3948993T3 (pl) Sposób mielenia generatora elektrochemicznego
IL290226A (en) Methods for identifying receptors for t cells
IL310814A (en) Methods for generating primary immune cells
SG11202011263RA (en) Method for preparing chimeric antigen receptor t cells by serum-free culture
IL278992A (en) Chimeric antigen receptor T cell therapy